Previous 10 | Next 10 |
Today marks the effective date for the U.S. Food and Drug Administration’s (FDA) final guidance document on bacterial risk control strategies for platelet collection and transfusion. This guidance for industry, “Bacterial Risk Control Strategies for Blood Collection Establ...
Cerus Corporation (Nasdaq: CERS) today announced its participation in the Society for the Advancement of Blood Management (SABM) Virtual Annual Meeting, which is scheduled for September 22-25, 2021. On Thursday, September 23, Cerus will host an industry workshop, “Clinical ne...
Cerus Corporation once again reports record growth, however, the market has throttled any momentum in the share price. Despite the lackluster price action, I remain bullish on CERS. The FDA compliance date in October is quickly approaching. It is possible we see a significant inflecti...
Cerus Corporation (Nasdaq: CERS) today announced that William ‘Obi’ Greenman, Cerus’ president and chief executive officer, and Kevin D. Green, Cerus’ chief financial officer, are scheduled to participate in the 2021 Cantor Global Virtual Healthcare Conferenc...
Cerus Corporation (Nasdaq: CERS) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has granted permanent Healthcare Common Procedure Coding System (HCPCS) Level II codes for Pathogen Reduced Cryoprecipitated Fibrinogen Complex, or INTERCEPT Fibrinogen Comp...
Gainers: BeyondSpring (NASDAQ:BYSI) +151%, Cerus (NASDAQ:CERS) +21%, Novavax (NASDAQ:NVAX) +18%, Global Blood Therapeutics (NASDAQ:GBT) +17%, SCWorx (NASDAQ:WORX) +14%. Losers: Flora Growth (NASDAQ:FLGC) -25%, Arcturus Therapeutics (NASDA...
Cerus (CERS +22.0%) announces the appointment of Ann Lucena to the company's board of directors. Lucena is the chief executive officer of San Ramon Regional Medical Center. Prior to her role at San Ramon Regional Medical Center, Lucena served as Chief of Staff for the Pres...
Cerus Corporation (Nasdaq: CERS) today announced the appointment of Ann Lucena, CEO of San Ramon Regional Medical Center (SRRMC), to its Board of Directors. SRRMC, a 123-bed acute care hospital located in the East Bay Area, is part of a joint venture involving Tenet Healthcare. She also...
Cerus Corporation (NASDAQ:CERS) has added ~14.8% in the pre-market after the company’s Q2 2021 financials and 2021 guidance came ahead of expectations. Cerus (CERS) has recorded its highest-ever quarterly revenue figure posting $37.8M in revenue to indicate ~41% YoY growth. The product...
Image source: The Motley Fool. Cerus Corporation (NASDAQ: CERS) Q2 2021 Earnings Call Aug 3, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Cerus Corporation (CERS) Q2 2021 Earnings Call Transcript
News, Short Squeeze, Breakout and More Instantly...
Cerus Corporation (Nasdaq: CERS) announced today that its second quarter 2024 financial results will be released on Thursday, August 1, 2024, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discu...
Cerus Corporation (Nasdaq: CERS) today announced the appointment of Dean Gregory to its Board of Directors. Mr. Gregory has a 30+-year career as a leader in the global blood transfusion and cell therapy industry, with broad experience across commercialization, product development, supply chain an...
Symposium and Abstracts Highlight Data from Real-world Implementation and Utilization of INTERCEPT Platelets and Plasma as well as from Red Blood Cell and LED Illuminator Programs Cerus Corporation (Nasdaq:CERS) today announced a lunch symposium and selection of abstracts at the 38 th...